Saturday 17 October 2026
Export TLSI’s income statement to Excel — free account
TriSalus Life Sciences, Inc.
TLSI Healthcare Medical Devices
TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024. In the quarter to June 2026, revenue grew 1.73%, EPS grew 40.7%, free cash flow fell 41.3% and total debt rose 2.45%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
3.63
0.27
−6.92%
Follow TLSI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.98 | 5.86 | 4.59 | 5.88 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(53.98) | (106.49) | (31.81) | (26.19) | |
P/B ratio |
0.00 | 0.00 | 16.10 | 40.50 | |
Price to Tangible BV |
0.00 | 0.00 | 17.63 | 48.79 | |
EV/Sales |
5.24 | 6.14 | 4.08 | 5.60 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.92) | (15.40) | (9.15) | (11.06) | |
EV/FCF |
(9.23) | (14.16) | (8.71) | (10.52) | |
Quick Ratio |
2.54 | 2.35 | 5.24 | 4.72 | |
Current Ratio |
3.05 | 2.80 | 5.78 | 5.35 | |
Net Debt/EBITDA |
(1.17) | (4.40) | 2.94 | 1.42 | |
Debt/Assets |
89.86% | 93.53% | 46.60% | 52.95% | |
Debt/Equity |
(1.23) | (0.98) | 2.58 | 5.05 | |
Asset Turnover |
1.26 | 1.52 | 0.90 | 0.87 | |
Operating CF/Net income |
0.09 | 0.30 | (4.21) | 1.10 | |
Capex/Depreciation |
(0.40) | (0.10) | (0.33) | (0.17) | |
Interest Coverage |
(6.17) | (2.25) | (5.86) | (6.59) | |
Research and Development Expense of Revenue |
44.75% | 23.46% | 36.14% | 27.50% | |
Selling, General and Administrative Expense of Revenue |
116.70% | 87.97% | 144.56% | 145.31% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
29.59% | 16.64% | 27.78% | 22.93% | |
Graham Net Nets |
(0.15) | (0.14) | 0.05 | 0.01 | |
Graham Number |
5.31 | 6.07 | 0.00 | 0.00 | |
Earnings Yield |
(43.44%) | (26.22%) | (35.25%) | (28.57%) | |
Free Cash Flow Yield |
(11.40%) | (7.40%) | (10.18%) | (9.04%) | |
Revenue per Share |
0.27 | 0.35 | 0.17 | 0.20 | |
Operating CF per Share |
(0.09) | (0.07) | (0.13) | (0.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.07) | (0.13) | (0.18) | |
Cash per Share |
0.53 | 0.54 | 1.10 | 0.79 | |
Shareholders Equity per Share |
(0.62) | (0.89) | 0.25 | 0.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.62) | (0.89) | 0.25 | 0.11 | |
Free Cash Flow |
(3.88) | (2.52) | (6.62) | (10.21) | |
Working Capital |
22.42 | 20.75 | 56.35 | 48.57 | |
Capital Expenditures |
(0.18) | (0.04) | (0.14) | (0.08) | |
Net Current Asset Value |
(29.86) | (36.95) | 9.97 | 3.85 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.96 | 5.82 | 5.33 | 6.02 | |
Average Payables |
2.62 | 2.64 | 3.52 | 2.83 | |
Average Inventory |
3.64 | 3.56 | 3.97 | 4.01 | |
Average Assets |
31.97 | 29.65 | 49.80 | 51.88 | |
Average Common Equity |
(23.58) | (29.88) | (10.78) | (6.44) |
Columns are period end dates